Cutting Edge Viral and Non-Viral Delivery Platforms for T-Cell Engineering and Beyond

Sponsored by: Thermo Fisher Scientific - Invitrogen

Speaker

Event Date & Time

DATE: March 26, 2020

TIME: 9:00am PST, 12:00pm EST

Abstract

Growing demand for precision therapy and the recent successes with CAR-T cells for cancer treatment has put the spot light on Cell and Gene Therapy Applications. However, the difficulty of delivering relevant payloads into immune and other challenging cells remains to be a major bottle neck to rapid advancement from bench to clinic. Most studies have been focused on using viruses to engineer T cells. At the same time due to safety concerns with viral vectors there is also lot of demand and investment in non-viral based methods to maximize gene editing efficiencies in immune cells especially to meet increasing demand for developing allogeneic immune cell therapies.

This talk will cover recent advancements we have made in delivery tools for genome editing, immune cell engineering and in vivo delivery applications. More specifically we will be addressing the following 4 focus areas.

Nucleic acid delivery solutions for hard-to-transfect primary & immune cell
Delivery of genome editing tools like CRISPR-Cas9 with electroporation or transfection reagents
Scalable and high yield Lentivirus production platform for cell and gene therapy applications
In vivo delivery of mRNA and siRNA with Invivofectamine™ reagents.

Learning Objectives:

Understand the difference between viral and non-viral delivery methods
Discover new technologies for T-Cell Engineering

Webinars will be available for unlimited on-demand viewing after live event.

LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

Cutting Edge Viral and Non-Viral Delivery Platforms for T-Cell Engineering and Beyond

Namritha Ravinder